%RiTEN - PhUSE 2007 Poster 07 Download

These are samples of what %RiTEN can do. Note %RiTEN can do these in different table styles and attributes as explained in the paper.

%RiTEN
Samples

www.tranz.co.uk

Table 001-01 Using RTF Control Words to Span Header Line

Spanning				
Name	Sex	Age	Height	Weight
Alfred	M	14	69	112.5
Alice	F	13	56.5	84
Barbara	F	13	65.3	98
Carol	F	14	62.8	102.5
Henry	M	14	63.5	102.5
James	M	12	57.3	83
Jane	F	12	59.8	84.5
Janet	F	15	62.5	112.5
Jeffrey	M	13	62.5	84
John	M	12	59	99.5
Joyce	F	11	51.3	50.5
Judy	F	14	64.3	90
Louise	F	12	56.3	77
Mary	F	15	66.5	112
Philip	M	16	72	150
Robert	M	12	64.8	128
Ronald	M	15	67	133
Thomas	M	11	57.5	85
William	M	15	66.5	112

Page 1 of 1

Program: t_span_header_line1.sas
Output: t_span_header_line_001_01.rtf (Date Generated: 31JUL07:14:55:06) Source Data: class.sas7bdat

Table 001-02 Using #byval in Title Statement

Treatment : Placebo

Name	Sex (N=xxx)	Age (N=xxx)
Alfred	M	14
Alice	F	13
Barbara	F	13
Carol	F	14
Henry	M	14
James	M	12
Jane	F	12
Janet	F	15
Jeffrey	M	13
John	M	12
Joyce	F	11
Judy	F	14
Louise	F	12
Mary	F	15
Philip	M	16
Robert	M	12
Ronald	M	15
Thomas	M	11
William	M	15

Page 1 of 2

Program: t_hash_byval1.sas
Output: t_hash_byval_001_02.rtf (Date Generated: 31JUL07:14:55:06) Source Data: class.sas7bdat

Table 002-01 Framing Cells

Height	name	sex	Weight
69	Alfred	M	112.5
56.5	Alice	F	84
65.3	Barbara	F	98
62.8	Carol	F	102.5
63.5	Henry	M	102.5
57.3	James	M	83
59.8	Jane	F	84.5
62.5	Janet	F	112.5
62.5	Jeffrey	M	84
59	John	M	99.5
51.3	Joyce	F	50.5
64.3	Judy	F	90
56.3	Louise	F	77
66.5	Mary	F	112
72	Philip	M	150
64.8	Robert	M	128
67	Ronald	M	133
57.5	Thomas	M	85
66.5	William	M	112

Page 1 of 2

Program: t_frame_cells1.sas
Output: t_frame_cells_002_01.rtf (Date Generated: 31JUL07:14:55:07) Source Data: class.sas7bdat

Table 002-02 Framing Cells

Maximum Post-Baseline	Group A			Group B		
	1	2	Total	1	2	Total
1	0	0	0	0	0	0
2	0	0	0	0	0	0
3	0	0	0	0	0	0
Total	0	0	0	0	0	0

Page 1 of 1

Program: t_frame_cells2.sas
Output: t_frame_cells_002_02.rtf (Date Generated: 31JUL07:14:55:08) Source Data: class.sas7bdat

Table 002-03 Cells Merging

	Placebo (N=xxx)	Drug (N=xxx)
Treatment Effects		
Least squares mean	xx.x	xx.x
SE	xx.x	xx.x
95% CI	(xx.x, xx.x)	(xx.x, xx.x)
Treatment Difference		
Least squares mean	xx.xxxxx	
SE	xx.xxxxx	
95% CI	(xx.xxxxx, xx.xxxxx)	

Page 1 of 1

Note the Treatment Difference lies between the treatments.

Program: t_cells_merging1.sas
Output: t_cells_merging_002_03.rtf (Date Generated: 31JUL07:14:55:09)
Source Data: dummy.sas7bdat

Table 003-01 Patient Profile

Name	Sex
Alfred	M

Age	Height	Weight
14	69	112.5
14	69	112.5
14	69	112.5
14	69	112.5
14	69	112.5

Program: t_patient_profile1.sas
Output: t_patient_profile_003_01.rtf (Date Generated: 31JUL07:14:55:10) Source Data: class.sas7bdat

Table 003-02 Patient Profile

name	Sex
Alfred	M

.

Age	Height	Weight
14	69	112.5
14	69	112.5
14	69	112.5
14	69	112.5
14	69	112.5

ref no
This is a very very long text

Program: t_patient_profile2.sas
Output: t_patient_profile_003_02.rtf (Date Generated: 31JUL07:14:55:11) Source Data: class.sas7bdat

Table 004-01 Stacking Tables

This act like a lid when all the tables are collapsed.

startdate	stopdate	aept
ddmmmyyy	ddmmmyyy	xxx yyy zzz
ddmmmyyy	ddmmmyyy	xxx yyy zzz

ref no
This is a very very long text

We can have a lid at the bottom also.

Note: SAS do not have 3 sided frame. This is done via post-processing.
Tables have not been collapsed for demonstration purpose. Set tgap=0 in %RiTEN to do so.

Program: t_stacking_tables1.sas
Output: t_stacking_tables_004_01.rtf (Date Generated: 31JUL07:14:55:12) Source Data: dummy.sas7bdat

Table 004-02 Stacking Tables

Objective Response Throughout the Study

	Pmab Plus BSC (N=xxx)		
Investigator	Response		No Response
Response	xx (%)		xx (%)
No Response	xx (%)		xx (%)
Kappa		xx.xx	
95% CI		(xx, xx)	
	BSC Alone (N=xxx)		
Investigator	Response		No Response
Response	xx (%)		xx (%)
No Response	xx (%)		xx (%)
Kappa		xx.xx	
95% CI		(xx, xx)	

Program: t_stacking_tables2.sas
Output: t_stacking_tables_004_02.rtf (Date Generated: 31JUL07:14:55:13) Source Data: dummy.sas7bdat

Table 004-03 Stacking Tables

Summary:

Stratum	Category	Treatment 1 (N=xxx)	Treatment 2 (N=xxx)
1	1	x.xx (x.xx)	x.xx (x.xx)
	2	x.xx (x.xx)	x.xx (x.xx)
	3	x.xx (x.xx)	x.xx (x.xx)
2	1	x.xx (x.xx)	x.xx (x.xx)
	2	x.xx (x.xx)	x.xx (x.xx)
	3	x.xx (x.xx)	x.xx (x.xx)

Test Statitics:

Statistics for Mean Score Difference	
Value	P-value
xx.x	<x.xxx

Program: t_stacking_tables3.sas
Output: t_stacking_tables_004_03.rtf (Date Generated: 31JUL07:14:55:14) Source Data: dummy.sas7bat

Table 005-01 Stacking Block Label

Age Group	Frequency Count
Male all Age	10
Female - Note This Label Can Span The Whole Table Width Because We Are Stacking This Label	
Age ≤ 13	5
Age > 13	4

Program: t_stack_block_label1.sas
Output: t_stack_block_label_005_01.rtf (Date Generated: 31JUL07:15:08:07) Source Data: class.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	101	00000001	Male	49	White or Caucasian	27JUN2000	05DEC2000

		Event Start							
Event Start Date	Event Stop Date	Day	Week	Duration (days)	System Organ Class [Preferred Term] / Verbatim Term	Severity [a]	Serious	Related	Action Taken [b]
20JUL2000	03AUG2000	24	4	15	Injury, poisoning and procedural complications [Arteriovenous graft thrombosis] / Thrombosis vascular access (avg)	Moderate	Yes	Yes	3,4
11NOV2000	11NOV2000	138	20	1	Injury, poisoning and procedural complications [Arteriovenous graft thrombosis] / Thrombosis vascular access (avg)	Moderate	Yes	Yes	3,4

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	101	00000001	Male	49	White or Caucasian	27JUN2005	05DEC2005

AER #UK3500, Arteriovenous graft thrombosis, 20JUL2000
Subject with chronic renal failure, hypotension following dialysis, a history of arteriovenous (AV) graft failure in the left arm and a history of recurrent stenosis and thrombosis of the AV graft,placed in the right arm for dialysis, was hospitalised with thrombosis of the vascular access approximately 23 days after initial exposure to treatment drug. The event improved followingthrombectomy and treatment with low molecular weight heparin and ticlopidine. Treatment with treatment drug was continued. The Investigator commented that the probable etiology was stenosis of the vein. A percutaneous angioplasty was performed and the event resolved. Mild hypotension following dialysis was noted during hospitalisation. TheInvestigator reported thrombosis of the vascular access moderate and stated that there was a reasonable possibility that the event may have been caused by treatment drug. Enoxaparin was considered co-suspect. Additional information received on 06/Sep/2000: Itwas confirmed that the subject only experienced an episode of mild hypotension after haemodialysis during hospitalisation, and no hypotension was detected post-operatively. Re-stenosis of the venasubclavia and vena brachiocephalica resolved. The Investigator reported re-stenosis moderate and stated that there was no reasonable possibility that the event may have been caused by the blindedstudy drug.

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	101	00000001	Male	49	White or Caucasian	27JUN2005	05DEC2005

AER #UK7787, Arteriovenous fistula thrombosis, 11NOV2000
Subject with chronic renal failure requiring dialysis and a history of recurrent arteriovenous (AV) graft stenosis and thrombosis, was hospitalised due to thrombosis of the vascular accessapproximately five months after initial exposure to treatment drug. The event improved. Treatment drug therapy was continued. The Investigator reported vascular access thrombosis moderate, andstated that there was a reasonable possibility that the event may have been caused by treatment drug. Additional information received on 12/Dec/2000: Phlebography, percutaneous transluminalangioplasty (PTA) and radiodiagnostic tests confirmed diagnosis. Thrombectomy and PTA were performed, and low molecular weight heparin was administered for the event. In the Investigator's opinion,previous cannulation and stenosis of the left descending subclavian vein was a risk factor for this event. The Investigator reported the low haemoglobin values severe and stated that there was noreasonable possibility that the event may have been caused by treatment drug.

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	102	00000002	Male	46	White or Caucasian	18AUG2000	29SEP2000

		Event Start							
Event Start Date	Event Stop Date	Day	Week	Duration (days)	System Organ Class [Preferred Term] / Verbatim Term	Severity [a]	Serious	Related	Action Taken [b]
06SEP2000	-	20	3	-	Congenital, familial and genetic disorders [Spondylolisthesis] / Worsening of lumbago-olisthesis of l4,l5	Moderate	Yes	No	3,4

AER #UK9547, Back pain, 06SEP2000
Subject with history of olisthesis was hospitalised with lumbago approximately nineteen days after initial exposure to treatment drug. He was administered intravenous guaifenesin, mesocain, sodiumand salicylicum. Apercutaneous transluminal angioplasty was performed eight days later. Additional information received on 24/Aug/2000: The subject was observed for transient postoperative hypotension and re-thrombosis during hospitalisation. Stenosis of central venous tract was considered to be a probable aetiology

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	103	00000003	Female	40	White or Caucasian	21SEP2000	01MAR2001

		Event Start							
Event Start Date	Event Stop Date	Day	Week	Duration (days)	System Organ Class [Preferred Term] / Verbatim Term	Severity [a]	Serious	Related	Action Taken [b]
27OCT2000	26NOV2000	37	6	31	Injury, poisoning and procedural complications [Arteriovenous fistula thrombosis] / Trombosis of avf	Moderate	Yes	No	4

AER #UK9095, Arteriovenous graft thrombosis, 27OCT2000
Subject with chronic renal failure, on dialysis, developed a thrombosis of the radiocephalic arteriovenous shunt and was hospitalised four weeks later, approximately nine weeks after initial exposureto treatment drug. Additional information wasreceived on 05/Aug/2000: Acute thrombosis was diagnosed by physical examination and after six days X-ray phlebography reported re-stenosis of the vena subclavia and vena brachiocephalica. The Investigator commented that the probable etiology was stenosis of the vein.

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	104	00000004	Male	63	White or Caucasian	25JUN2000	08DEC2000

		Event Start							
Event Start Date	Event Stop Date	Day	Week	Duration (days)	System Organ Class [Preferred Term] / Verbatim Term	Severity [a]	Serious	Related	Action Taken [b]
06AUG2000	18AUG2000	43	7	13	Renal and urinary disorders [Cystitis haemorrhagic] / Cystitis haemorrhagic	Moderate	Yes	No	3,4

AER #UK9548, Cystitis haemorrhagic, 06AUG2000
Subject was hospitalised with bleeding from the cystis urinae approximately six weeks after initial exposure to treatment drug. A cystoureteroscopy was performed and revealed haemorrhagic cystitis. A percutaneous angioplasty was performed and the event resolved. The Investigator reported theshunt thrombosis moderate and stated that there was no reasonable possibility that the event may have been caused by treatment drug. Treatment was started with ciprofloxacin. The event was resolving.

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	105	00000005	Male	43	White or Caucasian	11OCT2000	20MAR2001

		Event Start							
Event Start Date	Event Stop Date	Day	Week	Duration (days)	System Organ Class [Preferred Term] / Verbatim Term	Severity [a]	Serious	Related	Action Taken [b]
14DEC2000	27JAN2001	65	10	45	Surgical and medical procedures [Inguinal hernia repair] / Operatio hernia scrotalis	Severe	Yes	No	4

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat

Listing 1.1 Subjects Narratives of Serious Adverse Events
(Dummy Data)

Treatment Group	Centre	Subject	Sex	Age (yrs)	Race	Start Date of Study Drug	Stop Date of Study Drug
Placebo	106	00000006	Male	45	White or Caucasian	13OCT2000	23NOV2000

Event Start Date	Event Stop Date	Event Start Day	Event Start Week	Duration (days)	System Organ Class [Preferred Term] / Verbatim Term	Severity [a]	Serious	Related	Action Taken [b]
01NOV2000	05JAN2001	20	3	66	Investigations [Haemoglobin decreased] / Low hb value	Severe	Yes	No	3,4,5,7

AER #UK7050, Haemoglobin decreased, 05NOV2000
Subject with chronic kidney disease, on dialysis, and a history of gastric ulcer was hospitalised with low haemoglobin approximately one month after initial exposure to treatment drug. An endoscopywas performed and ulcus ventriculi verified. Study drug was withdrawn eighteen days later. The event resolved. The Investigator reported the haemorrhagic cystitis moderate and stated that there was no reasonable possibility that the event may have been caused by treatment drug.

[a] Severity: 01=Mild, 02=Moderate, 03=Severe, 04=Life Threatening, 05=Fatal
[b] Action Taken: 01=None, 02=Investigational product dose altered, 03=Medication taken, 04=Hospitalised, 05=Removed from study, 06=Investigational product discontinued, 07=Transfusion performed, 88=Other

Program: l_ae_narrative_arisg.sas
Output: l21_01_ae_narrative_arisg.rtf (Date Generated: 31JUL06:09:09:55) Source Data: ae.sas7bdat, aearisg.sas7bdat